Since the 1980’s, almost all production of generic drugs has moved overseas, where FDA inspectors have a much tougher time making sure they’re following rules for safety. An investigative journalist describes the ways she’s found that many drugmakers cut corners, putting safety at risk, and details what consumers can do to protect themselves.
Suddenly, cannabis-related, hemp-derived CBD is almost everywhere. CBD’s FDA status is murky, and we know very little about its benefits, thanks in part to its former place on DEA Schedule 1. How much has been proven about its supposed health qualities? What are the risks? Experts discuss in depth.